Imutec Corp., of Toronto, said it completed development and validation of a new potency assay for Virulizin, and is preparing to file documents to recommence clinical trials of the cancer drug in Canada, and start studies in the U.S. Trials were delayed in October 1994, while the company developed a reliable assay. * Procept Inc., of Cambridge, Mass., will reconfigure the dosing regimen in a Phase I/II trial of PRO 2000 for HIV...Patients in the Amsterdam study were having side effects associated

Cypros Pharmaceutical Corp., of Carlsbad, Calif., began multiple Phase II trials of its compound, CPC-111, to treat sickle cell anemia patients' ischemia, which is triggered by sickle-shaped red blood cells that clog capillaries...CPC-111 is a small molecule compound designed to generate cellular energy in the absence of oxygen. * Envirogen Inc., of Lawrenceville, N.J., was awarded a two-year, $646,000 contract from the U.S. Air Force for development of specialized bacteria to destroy chlorinated

* Chiron Corp., of Emeryville, Calif., and Ortho Diagnostic Systems Inc., of Raritan, N.J., entered into a settlement with Organon Teknika N.V., a company of the Netherlands-based Akzo Nobel Group, whereby Organon will pay compensation for infringing Chiron's U.K. and European hepatitis C virus patents. * Corixa Corp., of Seattle, entered into a collaboration with Belgium-based SmithKline Beecham Biologicals SA that will provide Corixa committed, multi-year funding for its research into

Cortex Pharmaceuticals Inc., of Irvine, Calif., paid Alkermes Inc., of Cambridge, Mass., a three-year $1 million promissory note to reacquire rights to calpain inhibitors for neurodegenerative disorders

The compound is an oligonucleotide believed to act by inhibition of HIV integrase and inhibition of cell fusion. * Cambridge NeuroScience Inc., of Cambridge, Mass., completed enrollment of its 120-patient Phase II dose- response study of Cerestat for stroke...28, 1995, initial public offering, bringing gross proceeds to $41.4 million. * Deprenyl Animal Health Inc., of Overland Park, Kan., received regulatory approval to market Anipryl for canine Cushing's disease in Canada

sold their technology for paclitaxel and other taxoid compounds to Korea-based Samyang Genex Co...Phase II trials are expected to begin early next year. * Interneuron Pharmaceuticals Inc., of Lexington, Mass., said the FDA's Endocrinologic and Metabolic Advisory Committee will meet Nov. 16, 1995, to take a final vote on its recommendation concerning the company's new drug application for dexfenfluramine, an anti-obesity drug. (See BioWorld Today, Sept. 29 and Oct. 2, 1995, p.1.) * Progenics

The shares are expected to be priced at $12 to $14 each...and Connaught Laboratories Ltd., a member of the Rhone-Poulenc Group, relating to ID's tuberculosis vaccine technology

Alpha 1 Biomedicals Inc., of Bethesda, Md., settled a class action lawsuit related to statements concerning its product, thymosin alpha 1...The extension relates to development of the Texas company's Novastan to treat heparin- induced thrombocytopenia conditions. (c) 1997 American Health Consultants

Andrulis Pharmaceuticals Corp., of Beltsville, Md., started a Phase I/II trial of thalidomide for multiple sclerosis. * Avid Therapeutics Inc., of Philadelphia, exercised its option to license a class of antiviral compounds, known as polyoxometalates, from researchers at Atlanta-based Emory University. * Biomatrix Inc., of Ridgefield, N.J., received notification that its premarket approval application for Hylaform _ a hylan polymer for correction of facial wrinkles and depressed scars _ was

59007 relating to a genetically engineered hepatitis B vaccine...The decision allows BTG to produce and market its third-generation vaccine in Israel and perhaps other countries, while paying a royalty to Biogen. * Chiron Corp., of Emeryville, Calif., said the merger of San Diego-based Viagene Inc

59007 relating to a genetically engineered hepatitis B vaccine...The decision allows BTG to produce and market its third-generation vaccine in Israel and perhaps other countries, while paying a royalty to Biogen. * Chiron Corp., of Emeryville, Calif., said the merger of San Diego-based Viagene Inc

The additional funds were collected when underwriters for the offering exercised options to purchase 425,000 shares registered to cover overallotments

Genzyme Trangenics Corp., of Framingham, Mass., agreed to sell G.D.R.U. Ltd., of London, to Quintiles Corp., of Research Triangle Park, N.C., for $9.5 million in cash...and European marketing rights to its AccuSite injectable gel from U.K.-based Medeva plc

An item in the Other News To Note column of the Sept

Ampakines are designed to target diseases linked to depressed functioning of the glutamatergic pathways in the brain. * Pharmos Corp., of New York and Alachua, Fla., raised $9 million through the sale of 6 million units, which consist of one share of common stock and one warrant to purchase .075 shares at $1.80 per share

The tests will help detect antibodies to infectious mononucleosis, group A streptococcus, rheumatoid arthritis (two tests), and to help detect C-reactive protein, which relates to tissue injury

The study will involve up to 90 patients. * Ostex International Inc., of Seattle, settled its trade name litigation with Ostech Inc., of New Haven, Conn., after the latter agreed to change its business title to Norland Medical Systems Inc. * Perkin-Elmer Corp., of Norwalk, Conn., entered an agreement with the U.K.-based Oxford Molecular Group plc to develop computer software aimed at accelerating and broadening the scope of DNA sequencing...Ampakines are designed to target diseases linked to

Allovectin- 7 is designed to deliver to tumor cells a gene encoding a foreign tissue antigen, which is expected to trigger an immune system attack against the cancerous cells

Allovectin- 7 is designed to deliver to tumor cells a gene encoding a foreign tissue antigen, which is expected to trigger an immune system attack against the cancerous cells